Exosomes: Decreased sensitivity of lung cancer A549 cells to cisplatin

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Xiao, Xia ^a   Yu, Shaorong ^a   Li, Shuchun ^b   Wu, Jianzhong ^a   Ma, Rong ^a   Cao, Haixia ^a   Zhu, Yanliang ^c   Feng, Jifeng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING TECH UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MESSENGER RNA; MICRORNA;

ARTICLE; CANCER CELL; CELL COMMUNICATION; CELL VACUOLE; CELL VIABILITY; CELLULAR SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESISTANCE; DRUG SENSITIVITY; EXOSOME; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EXOSOMES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; RNA, MESSENGER;

EID: 84896760337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089534     Document Type: Article

References (29)

1. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535. (Pubitemid 351738162)
2. Eastman A. (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155-166.
3. Halazonetis TD, Gorgoulis VG, Bartek J. (2008) An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355. (Pubitemid 351354863)
4. Zhang G, Sun L, Lu X, Chen Z, Duerksen-Hughes PJ, et al. (2012) Cisplatin treatment leads to changes in nuclear protein and microRNA expression. Mutat Res 746: 66-77.
5. Gately DP, Howell SB. (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176. (Pubitemid 23172848)
6. Shellard SA, Fichtinger-schepman AM, Lazo JS, Hill BT. (1993) Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500. (Pubitemid 23253708)
7. Galluzzi L, Moreslli E, Vitale I, Kepp O, Senovilla L, et al. (2010) MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70: 1793-1803.
8. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303. (Pubitemid 32224344)
9. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, et al. (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305. (Pubitemid 34874721)
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-659. (Pubitemid 47214727)
11. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. (2013) Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 113: 1-11.
12. Whiteside TL. (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41: 245-251.
13. Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, et al. (2013) Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett 335: 201-204.
14. SKOG J, Wuringer T, Van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
15. Corcoran C, Rani S, O'brien K, O'Neilll A, Prencipe M, et al. (2012) Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 7: e50999.
16. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, et al. (2005) Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4: 1595-1604. (Pubitemid 41556443)
17. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, et al. (2010) Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 5: e13247.
18. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, et al. (2012) Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells 30: 1556-1564.
19. Gao W, Lu X, Liu L, Xu J, Feng D, et al. (2012) MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 13: 330-340.
20. Xiang Q, Tang H, Yu J, Yin J, Yang X, et al. (2013) MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. Pharmazie 68: 274-281.
21. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, et al. (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 388: 483-489.
22. Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, et al. (2013) MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 31: 56-65.
23. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, et al. (2010) MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70: 1793-1803.
24. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216.
25. Jiang JW, Liang XH, Zhou XL, Huang R, Chu Z, et al. (2012) ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 39: 6933-6942.
26. Gao Y, Zhu J, Zhang X,Wu Q, Jiang S, et al. (2013) BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/ Chemoradiotherapy. PLoS One 8: e52589.
27. Zhou C, Zhou S, Zhang L. (2009) RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy. J Clin Oncol 27: 8097.
28. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, et al. (2011) MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm 8: 1381-1389.
29. Eldh M, Ekstrom K, Valadi H, Sjostrand M, Olsson B, et al. (2010) Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One 5: e15353.